ABSTRACT 17
Staphylococcus aureus infections represent the major cause of titanium based-orthopaedic implant 18 failure. Current treatments for S. aureus infections involve the systemic delivery of antibiotics and 19 additional surgeries, increasing health-care costs and affecting patient's quality of life. As a step 20 toward the development of new strategies that can prevent these infections, we build upon previous 21
work demonstrating that the colonization of catheters by the fungal pathogen Candida albicans 22
can be prevented by coating them with thin polymer multilayers composed of chitosan (CH) and 23 hyaluronic acid (HA) designed to release a β-amino acid-based peptidomimetic of antimicrobial 24 peptides (AMPs). We demonstrate here that this β-peptide is also potent against S. aureus (MIC = 25 4 µg/mL) and characterize its selectivity toward S. aureus biofilms. We demonstrate further that 26 β-peptide-containing CH/HA thin-films can be fabricated on the surfaces of rough planar titanium 27 substrates in ways that allow mammalian cell attachment and permit the long-term release of β-28
peptide. β-Peptide loading on CH/HA thin-films was then adjusted to achieve release of β-peptide 29
quantities that selectively prevent S. aureus biofilms on titanium substrates in vitro for up to 24 30 days and remained antimicrobial after being challenged sequentially five times with S. aureus 31 inocula, while causing no significant MC3T3-E1 preosteoblast cytotoxicity compared to uncoated 32
and film-coated controls lacking β-peptide. We conclude that these β-peptide-containing films 33 offer a novel and promising localized delivery approach for preventing orthopaedic implant 34
infections. The facile fabrication and loading of β-peptide-containing films reported here provides 35
opportunities for coating other medical devices prone to biofilm-associated infections. 36 37 KEYWORDS: Biofilms, Antimicrobial β-peptides, S. aureus, Polyelectrolyte multilayers, 38
Titanium substrates 39 40
STATEMENT OF SIGNIFICANCE: 41
Titanium (Ti) and its alloys are used widely in internal fixation devices due to their mechanical 42 strength and long-term biocompatibility. However, these devices are susceptible to bacterial 43 colonization and the subsequent formation of biofilms. Here we report a chitosan and hyaluronic 44 acid polyelectrolyte multilayer-based approach for the localized delivery of helical, cationic, 45
globally amphiphilic β-peptide mimetics of antimicrobial peptides to inhibit S. aureus colonization 46 and biofilm formation. Our results reveal that controlled release of this β-peptide can selectively 47 kill S. aureus cells without exhibiting toxicity toward MC3T3-E1 preosteoblast cells. Further 48 development of this polymer-based coating could result in new strategies for preventing 49 orthopaedic implant-related infections, improving outcomes of these titanium implants. 50 51 52 infection [20, 23] . For the treatment of MRSA infections, combination therapy including 76 vancomycin, dicloxacillin, linezolid, daptomycin and fosfomycin antibiotics is often needed 77 [16, 24] . In addition to the severe side effects associated with the systemic delivery of antibiotics 78 and the emergence of resistant S. aureus strains, antibiotic treatment for IFD-associated infections 79 faces challenges such as poor antibiotic bioavailability in bone tissue and antibiotic resistance in 80 bacterial biofilms [12, 14, 21, 22] . In view of these challenges, there is a critical need for the 81 development of new strategies preventing microbial infections associated with IFDs. 82
Antimicrobial peptides (AMPs) and peptidomimetic analogs of AMPs have been studied as 83 potential new classes of antimicrobials. These AMPs are part of the host's adaptive immune system 84 and often display selective toxicity to microbial cells vs. host cells [25, 26] . Structural characteristics 85 such as an overall net positive charge and adopting a global amphiphilic conformation (e.g., α-86 helix) upon contact with microbial surfaces confer antimicrobial activity [27, 28] . The proposed 87 toxicity mechanism of many types of AMPs involves disruption of the microbial cell membrane, 88 leading to membrane permeabilization, cell lysis and subsequent death [25, 29] . Given the lack of a 89 single target of AMPs, the development of bacterial resistance to AMPs and their mimetics is 90 thought to be less likely than for traditional antibiotics [26, 30] . 91
While AMPs hold promise as antimicrobials, their structural instability under physiologic 92 conditions and susceptibility to protease degradation in vivo have limited their development as 93 antimicrobials [31] [32] [33] [34] . Recently, β-peptide foldamers have emerged as cationic, globally 94 amphiphilic structurally stable peptidomimetics. β-Peptides have been demonstrated to have strong 95 antibacterial activity against planktonic Gram-positive and Gram-negative bacteria [28, 29, [35] [36] [37] [38] [39] . 96
Motivated by the potential of β-peptides as an alternative antimicrobial treatment, we have 97 previously demonstrated 14-helical β-peptide toxicity toward planktonic Candida albicans cells 98 and prevention of C. albicans biofilms in vitro [28, 37, 40, 41] . Our previous work also identified the 99 (ACHC-β 3 hVal-β 3 hLys)3 β-peptide (Scheme 1) as a promising antimicrobial candidate due to its 100 strong activity against planktonic C. albicans cells (MIC = 4 µg/mL), ability to prevent C. albicans 101 biofilm formation (MIC = 8 µg/ml) and good selectivity to microbial cells (2.3 ± 0.7% hemolysis 102 at planktonic MIC) [37, 40] . Here we build upon our previous work to evaluate the ability of 103 (ACHC-β 3 hVal-β 3 hLys)3 β-peptide to inhibit the formation of S. aureus biofilms and selectivity 104 to S. aureus vs. preosteoblast cells 105 106 Scheme 1: Chemical structure of 14-helical (ACHC-β 3 hVal-β 3 hLys)3 β-peptide used in this study. 107
In an effort to improve the selectivity of AMPs and AMP mimetics, increase activity against 108 microbial cells and reduce the toxicity associated with a systemic delivery, strategies that can 109 localize their delivery to sites prone to infection have recently emerged as an alternative treatment 110 for IFD-related infections. Polyelectrolyte multilayer (PEM) coatings have been developed as a 111 localized platform for surface-mediated release of active biological agents such as growth factors 112 (e.g., BMP-2, bFGF), β-peptides, antibiotics, DNA, among other active agents [22, [42] [43] [44] [45] . We 113 have also recently reported the prevention of C. albicans colonization and biofilm formation in 114 vitro and in vivo on catheters coated with either polyglutamic acid / poly-L-lysine (PGA/PLL) or 115 chitosan /hyaluronic acid (CH/HA) PEM films loaded with β-peptide [43, 46, 47] . Motivated by 116 that past work, we focus here on demonstrating the potential use of β-peptide-containing PEM 117 coatings fabricated on the surfaces of rough titanium substrate surfaces for preventing S. aureus-118 related infections. We further evaluated the biocompatibility of these coatings with model 119 osteogenic mammalian cells (MC3T3-E1 preosteoblast). Our results suggest that the controlled 120 release of β-peptide quantities selective only to microbial cells can be achieved using minor 121 modifications, such as chemical crosslinking and by tuning the β-peptide loading. Specifically, our 122 results reveal that β-peptide-containing films deposited on titanium substrates surfaces can release 123 sufficient quantities of β-peptide to prevent S. aureus biofilm formation in vitro for up to 24 days 124 and five bacterial challenges. Overall, the results reported here indicate β-peptide-containing PEMs 125 coatings to be a useful platform for the design of antibacterial coated IFDs for inhibiting S. aureus 126 biofilm formation. 127 128
Materials and Methods 129

Materials 130
Branched polyethyleneimine (BPEI, MW=25,000), chitosan (CH, medium molecular weight), 131 phosphate-buffered saline (PBS), paraformaldehyde, glutaraldehyde, menadione, filtered water for 132 cell culture, fluorescein-labeled hyaluronic acid, chloramphenicol, and medical grade titanium 133 disks were purchased from Sigma-Aldrich. Sodium hyaluronate (HA, MW 1,5000,000-2,200,000) 134 was purchased from Acros Organic. 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-135 5-carboxanilide (XTT), RPMI 1640 powder containing L-glutamine and phenol red (without 136 HEPES or Na bicarbonate), penicillin-streptomycin (10,000 U/mL), NaCl, 3-(N-137 morpholino)propanesulfonic acid (MOPS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 138 hydrochloride (EDC), N-hydroxysulfosuccinimide (Sulfo-NHS), Calcein-AM, ethidium 139 homodimer-1, Hoechst 33342, Nunc™ Lab-Tek™ II Chamber Slide™ System, and Pierce™ 140
Quantitative Fluorometric Peptide Assay were purchased from Thermo Fisher Scientific. α-MEM 141 (1x) minus ascorbic acid was obtained from Gibco. Osmium tetroxide (4%) was obtained from 142 Electron Microscopy Sciences. Accutase was purchased from Innovative Cell Technologies. Cell 143
Titer Glo 2.0 assay kits were obtained from Promega. All materials were used as received. 144
General Considerations 145
β-Peptide (ACHC-β 3 hVal-β 3 hLys)3 was synthesized using previously reported methods [37] . 146
Titanium substrates were cut to 0.6 cm width x 1.8 cm length dimensions, cleaned with acetone, 147 ethanol, methanol, and deionized water, dried under a stream of filtered and compressed air, and 148 plasma etched for 1800s (Plasma Etch, Carson City, NV) prior to the fabrication of PEM films. 149
Uncoated, film-coated and β-peptide-loaded titanium substrates were UV sterilized for 15 min per 150 side using a biosafety cabinet prior to biological experiments. Fluorescence microscopy images 151
were obtained with an Olympus IX70 epifluorescence microscope using Nikon NIS image 152 acquisition software. Fiji Image J was used to create merged images and quantify fluorescence 153
intensities. Critical point drying, sputtering and scanning electron microscopy (SEM) were 154 performed using a Leica EM CPD 300 critical point dryer, Leica ACE600 Sputter, and a LEO 155 SEM microscope at 5kV. Fluorescence measurements to characterize β-peptide release, 156 absorbance measurements to quantify S. aureus cell viability, and luminescence measurements to 157 quantify MC3T3-E1 cell viability were taken with a Tecan M200 multi-well plate reader. 158
Characterization of β-peptide antimicrobial minimum inhibitory concentration (MIC) and
159
MC3T3-E1 preosteoblast cell cytotoxicity 160
The antimicrobial activity of (ACHC-β 3 hVal-β 3 hLys)3 β-peptide against S. aureus biofilms was 161 assayed in 96-well plates according to susceptibility testing guidelines provided by the Clinical 162
and Laboratory Standards Institute [48] . The broth microdilution assay methods were modified to 163 include the quantitative assessment of cell viability using XTT. An aliquot of 100 µL of two-fold 164 serial dilutions of β-peptide in MH medium + 0.5% glucose was mixed with 100 µL of S. aureus 165 (grown in TSB medium overnight at 37°C and concentration adjusted to 10 6 CFU/mL) cell 166 suspension and the plates were incubated for 24 hr at 37°C to allow biofilm formation. Wells 167 lacking β-peptide and wells lacking cells and β-peptide were included as controls. After 24 hr, 168 100 µL of XTT solution (0.5 g/L in PBS, pH 7.4, containing 3 µM menadione in acetone) was 169 added to all wells, and plates were incubated at 37°C in the dark for 1 hr. The supernatants (75 µL) 170
were transferred to a new 96-well plate and absorbance at 490 nm was recorded. The cell viability 171 was normalized to the untreated control and plotted as a function of β-peptide concentration. The 172 lowest assayed concentration of β-peptide that resulted in a decrease in absorbance of at least 90% 173 of the mean was determined to be the minimum inhibitory concentration (MIC) of the peptide. 174 MC3T3-E1 cell toxicity was assessed using the Cell Titer Glo protocol to quantify the 175 amount of ATP present in metabolically active cells. MC3T3-E1 cells were cultured in MEMα 176 medium supplemented with 10% FBS, 1% of penicillin-streptomycin, in a humidified incubator at 177 37°C and 5% CO2 in air. Upon reaching 100% confluency, cells were detached using Accutase, 178 centrifuged and resuspended in MEMα medium to a final concentration of 5x10 4 cells/cm 2 . An 179 aliquot of 100 µL of two-fold serial dilutions of β-peptide in MEMα medium was mixed with 100 180 µL of the MC3T3-E1 cell suspension and the plates were incubated for 24 hr at 37°C and 5% CO2 181 in air. Wells lacking β-peptide and wells lacking cells and β-peptide were included as controls. 182
Afterwards, Cell Titer Glo reagent (100 µL) was added into each well, incubated for 5 min, and 183 the luminescence signal was recorded. The percent of cell death in each well was calculated as: 184
where RLUcontrol represents the luminescence signal of untreated control (well lacking β-peptide) 186
and RLUpeptide represents the luminescence signal of β-peptide-containing samples. The percent of 187 cell death was plotted as a function of β-peptide concentration to generate the dose-response curve 188 for MC3T3-E1 toxicity. The IC20 value was determined as the β-peptide concentration that resulted 189 in 20% death of MC3T3-E1 cells. 190
Fabrication of polyelectrolyte multilayers films on the surfaces of titanium substrates 191
Solutions of HA and BPEI (1 mg/mL) were prepared in deionized water containing 0.15 M NaCl. 192 CH solution (1 mg/mL) was prepared in 0.1 M acetic acid and deionized water containing 0.15 M 193
NaCl. PEMs were fabricated on the surfaces of cut, cleaned, and plasma etched titanium substrates 194 using the following general protocol: (1) substrates were submerged in the 1 mg/mL BPEI solution 195 for 30 min, (2) substrates were removed and immersed in a rinse bath of deionized water containing 196 0.15 M NaCl for 1 min, followed by a second rinse bath for 1 min, (3) substrates were immersed 197 in the 1 mg/mL CH solution for 5 min, (4) substrates were removed and rinsed as described in step 198 2, (5) substrates were immersed in the 1 mg/mL HA solution for 5 min, (6) substrates were 199 removed and rinsed as described in step 2 and steps 3-6 were repeated until a total of 19.5 bilayers 200 were deposited. For experiments designed to characterize film growth profiles, PEMs were 201 fabricated as described above but using fluorescein-labeled hyaluronic acid. Fluorescence images 202 from 3 different regions of the PEM-coated titanium substrate were taken after 4.5, 9.5, 14.5 and 203 19.5 bilayers were deposited. The fluorescence intensities of these images were quantified using 204
Fiji Image J software. 205
Chemical crosslinking of PEM films deposited on titanium substrates 206
CH/HA PEMs films were chemically crosslinked by immersing PEM-coated titanium substrates 207 in a 400 mM EDC/100 mM Sulfo-NHS solution in deionized water containing 0.15 M NaCl for 208 16 hr at room temperature. Next, substrates were rinsed 3 times for 30 min each in fresh deionized 209 water containing 0.15 M NaCl, followed by a drying using filtered and compressed air. An 210 uncoated control titanium substrate was immersed in deionized water containing 0.15 M NaCl 211 without crosslinking agents for 16 hrs as control. For epifluorescence microcopy to characterize 212 the films before and after crosslinking, CH/HA films were fabricated using fluorescein-labeled 213 HA and fluorescence images were taken before and after crosslinking. 214
Characterization of crosslinked films using PM-IRRAS 215
To characterize CH/HA PEM film crosslinking, CH/HA PEMs films were deposited on gold-216 coated silicon substrates and crosslinked as described above. Crosslinking was characterized by 217 polarization-modulation infrared reflectance-absorbance spectroscopy (PM-IRRAS) conducted in 218 a similar fashion to previously reported methods [49] . Briefly, gold-coated silicon substrates 219 coated with CH/HA PEM films before and after crosslinking were placed in a Nicolet Magna-IR 220 860 Fourier transform infrared spectrophotometer equipped with a photoelastic modulator (PEM-221 90, Hinds Instruments, Hillsboro, OR), a synchronous sampling demodulator (SSD-100, GWC 222
Technologies, Madison WI), and a liquid nitrogen cooled mercury-cadmium-telluride detector. 223
The modulation was set at 5865.0 nm, 0.5 retardation and 500 scans with a resolution of 2 cm -1 224
were obtained for each sample. The differential reflectance infrared spectra were normalized and 225 converted to absorbance spectra using a previously reported procedure [49] . air. An uncoated control titanium substrate was immersed in deionized water containing 0.15 M 232 NaCl without β-peptide for 24 hrs. Similarly, a PEM film-coated control was immersed in in 233 deionized water containing 0.15 M NaCl without β-peptide for 24 hr. 234
Estimation of film thickness 235
The thicknesses of CH/HA, crosslinked CH/HA, and β-peptide-loaded CH/HA films on titanium 236 substrates were estimated using focused ion beam scanning electron microscopy (FIB-SEM). β-237
Peptide loaded CH/HA films were prepared as described before. Uncrosslinked CH/HA films were 238 incubated for a total of 30 hrs in deionized water containing 0.15 M NaCl as a control lacking 239 crosslinking solution and β-peptide. Similarly, control crosslinked CH/HA films were incubated 240 in deionized water containing 0.15 M NaCl and lacking β-peptide for 24hrs. Samples were 241 platinum-palladium coated and 1 rectangular section 10 µm wide was milled using a 0.10 nA 242 electrical current to create a film cross-section. Five different regions within the milled section 243 were selected to estimate the film thickness using SEM at 2kV. A biological and XTT metabolic activity assay configuration similar to that described above 279 was used to evaluate biofilm formation after multiple S. aureus challenge experiments and after 280 incubation of substrates in PBS prior to biofilm formation. For the multiple challenge experiments, 281 uncoated, film-coated, and β-peptide loaded titanium substrates were initially incubated with an S. 282 aureus inoculum and biofilms were allowed to grow for 24 hr (challenge 1). Substrates were then 283 incubated in PBS for an additional 2 days and subsequently challenged with an additional S. aureus 284 inoculum for 24 hr (challenge 2). This multiple-challenge process was repeated until 5 different S. 285 aureus challenges were achieved, for a total of 18 days. Different sets of titanium substrates were 286 sacrificed after 1, 2, 3, 4, and 5 challenges and XTT metabolic assays were performed to quantify 287 biofilm formation. For the PBS pre-incubation experiments, uncoated, film-coated, and β-peptide 288 loaded titanium substrates were incubated in PBS at 37°C for the specified period of time (e.g., 1, 289 2, 4, 6, 12, 24, 36, 48, and 60 days) and then challenged with an S. aureus inoculum. Extents of 290 biofilm formation were quantified via XTT assay and data were normalized to the uncoated 291
control. 292
To analyze biofilm formation using fluorescence microscopy, a GFP-expressing S. aureus 293 strain AH1756 was used. Following 24 hr biofilm formation at 37°C, uncoated, film-coated, and 294 β-peptide loaded titanium substrates were washed with PBS and biofilm growth was inspected 295 under an epifluorescence microscope. We also evaluated S. aureus biofilm morphology using 296 SEM. For this analysis, uncoated, film-coated, and β-peptide loaded titanium substrates were 297 prepared using a previously published protocol [43, 46] . Briefly, titanium substrates were placed 298 in a fixative solution (1% (v/v) glutaraldehyde and 4% (v/v) paraformaldehyde) overnight at 4 °C. 299
Next, titanium substrates were rinsed with PBS for 10 min and placed in osmium tetroxide (1%) 300 for 30 min, followed by another wash in PBS for 10 min. Titanium substrates were then dehydrated 301 using a series of ethanol washes (30%, 50%, 70%, 85%, 95% and 100%, 10 min each) and final 302 desiccation was performed using critical point drying. Finally, specimens were mounted in 303 aluminum stubs and sputter-coated with a 12 µm thick layer of platinum-palladium. Samples were 304 then imaged by SEM in high-vacuum mode at 5kV. 305
2.11.
Biocompatibility of β-peptide-loaded PEM films 306 MC3T3-E1 cells were grown in MEMα medium, supplemented with 10% FBS and 1% penicillin-307 streptomycin, in a humidified incubator at 37°C and 5% CO2 in air. Culture medium was 308 replenished every 2-3 days and cells were sub-cultured using Accutase when near-100% 309 confluency was observed. All cells used in these studies were less than passage number 25. 310
Uncoated, film-coated, and β-peptide loaded titanium substrates were placed inside four-well Lab 311
Tek chambers containing 750 µL of an MC3T3-E1 cell suspension adjusted to a cell density of 312 5x10 4 cells/cm 2 in α-MEM and incubated for 24 hr at 37°C and 5% CO2, unless otherwise 313 specified. MC3T3-E1 cell viability was characterized using (i) a Cell Titer Glo metabolic activity 314 assay and (ii) by visualizing MC3T3-E1 cell attachment with fluorescence microscopy. 315
Cell Titer Glo assessment of MC3T3-E1 cell metabolic activity was performed according to 316 the manufacturer's recommendations. Briefly, uncoated, film-coated, and β-peptide loaded 317 titanium substrates were removed from the four-well Lab Tek chambers, gently washed with PBS 318 and transferred into a new and unused Lab Tek chamber. MEMα medium and Cell Titer Glo 319 reagent (750 µL each) were added into the wells and incubated for 5 min. Next, 180 µL of 320 supernatant was transferred into a 96-well plate and luminescence signal was quantified. 321
Background luminescence from wells containing medium and Cell Titer Glo was subtracted from 322 all readings and data were normalized relative to the uncoated titanium control. For the PBS pre-323 incubation experiments, uncoated, film-coated, and β-peptide-loaded titanium substrates were 324 allowed to elute β-peptide in PBS at 37°C for the specified period of time (e.g. 1, 2, 4, 6, 12, 24, 325 36, 48 and 60 days). MC3T3-E1 cells were then seeded on the films and allowed to attach and 326 grow for 24 hr. Viability of the MC3T3-E1 cells was then quantified using the Cell Titer Glo assay. 327
Fluorescence microscopy images of MC3T3-E1 cells on the surfaces of uncoated, film-coated, 328
and β-peptide-loaded titanium substrates were acquired as previously described [22] . Briefly, each 329 titanium substrate was placed inside a four-well Lab Tek chamber containing 750 µL of a MC3T3-330 E1 cell suspension adjusted to a cell density of 5x10 4 cells/cm 2 in MEMα medium and incubated 331 for the specified period of time (e.g. 2, 4, and 6 days) at 37°C and 5% CO2. Afterwards, a working 332 solution of 2 µM Calcein-AM, 4 µM ethidium homodimer-1 and 0.2 mg/mL Hoechst 33342 was 333 prepared in PBS and then incubated with the cells on Ti substrates for 30 min at 37°C. The dye 334 solution was gently aspirated from the wells, and then substrates were rinsed with PBS and imaged 335 using an epifluorescence microscope. Although strong antimicrobial activity is highly desired, evaluating selectivity to S. aureus cells 359 exclusively is also crucial for potential use to prevent IFD-related infections in vivo. We therefore, 360 investigated (ACHC-β 3 hVal-β 3 hLys)3 β-peptide biocompatibility with MC3T3-E1 preosteoblast 361 subclone 4 cells, a model mammalian cell line with osteoblast differentiation capacity and 362 mineralization activity. Our results showed a concentration-dependent β-peptide toxicity toward 363 MC3T3-E1 preosteoblast cells with an inhibitory concentration resulting in 20% cell death (IC20) 364 of 22.6 ± 7.4 μg/mL (Figure 1 , blue circles). We defined an in vitro selectivity index (SI) as the 365 ratio of β-peptide cytotoxicity (IC20) against MC3T3-E1 cells to MIC against inhibiting S. aureus 366 biofilm formation (SI= IC20/MIC). Using this approach, (ACHC-β 3 hVal-β 3 hLys)3 β-peptide was 367 demonstrated to have a SI value of 5.7, suggesting good selectivity for S. aureus vs. MC3T3-E1 368 cells. This result motivated the development of delivery strategies for its localized release for 369 preventing S. aureus biofilm formation. 370 371
Fabrication and characterization of β-peptide-containing PEM films 372
We selected the polysaccharide-based CH/HA PEM film system for use in this study because 373 these coatings have been well-studied as a platform for the localized release of active agents from S. aureus cells (10 6 cells/mL) were incubated with the indicated βpeptide concentrations in MH medium + 0.5% glucose in 96-well plates for 24 hr at 37°C, and then biofilm was quantified using an XTT assay. Biofilm viability was normalized to a control lacking β-peptide. The arrow indicates the MIC for inhibiting S. aureus biofilm formation. To evaluate β-peptide cytotoxicity, we incubated MC3T3-E1cells (5x10 4 cells/cm 2 ) with the indicated β-peptide concentrations in MEM α medium in 96-well plates for 24 hr at 37°C and 5% CO2. MC3T3-E1 cell viability was quantified using a Cell Titer Glo assay. Cell death was calculated based on the percent change with respect to the cells grown in the absence of peptide. The dashed red line indicates the IC20 β-peptide concentration. Data points represent the mean values and error bars the standard deviation of three independent experiments. segments using an iterative flow-based approach prevented C. albicans biofilms in vitro and in 378 vivo. This current study sought to extend upon that prior work to (i) determine whether CH/HA 379 PEMs fabricated on rough and planar titanium substrates could be used to promote the long-term 380 release of β-peptide and prevent formation of S. aureus-related biofilms, (ii) evaluate the 381 biocompatibility of β-peptide-loaded PEM films with the MC3T3-E1 preosteoblast cell line, and 382 (iii) assess the selectivity of these β-peptide-containing coatings against S. aureus vs. MC3T3-E1 383
cells. 384
Using an iterative immersion-based layer-by-layer assembly approach, we deposited CH/HA 385 multilayers on the surfaces of titanium substrates ( Figure 2 ) and characterized their growth by 386 monitoring the fluorescence intensity of FITC-labeled HA incorporated within the films, using a 387 previously published approach consisting of imaging and analyzing the fluorescence intensity after 388 the deposition of every five CH/HA bilayers [46] . As shown in Figure 2 , the average fluorescence 389 intensity increased with the number of CH/HA bilayers deposited, consistent with layer-by-layer 390 film growth [56] . 391
392
We then characterized the ability of MC3T3-E1 preosteoblast cells to attach and proliferate on 393 Figure S2 ). Our results demonstrate that, after 416 crosslinking, the surface remained covered by the films (Figure 2F, S2B ), similar to control 417 CH/FITC-HA films that were incubated in deionized water containing 0.15 M NaCl ( Figure S2C) . 418
We confirmed CH/HA film crosslinking using polarization modulation infrared reflection-419 absorption spectroscopy (PM-IRRAS). Because PM-IRRAS requires a reflective surface, we 420 deposited the CH/HA PEMs on gold-coated silicon wafers and obtained the infrared spectra of the 421 films before and after EDC/NHS crosslinking. Inspection of the spectra revealed disappearance of 422 the HA carbonyl group at 1412 cm -1 after film crosslinking ( Figure S3 ), consistent with the 423 formation of an amide bond between CH and HA. Additionally, we observed that the crosslinked 424 films had a strong absorbance in the amide I (1660 cm -1 ) and amide II bands (1570 cm -1 ), further 443 suggesting the successful crosslinking of the CH/HA films ( Figure S3 ). We then compared MC3T3-444 E1 cell adhesion and proliferation on crosslinked and uncrosslinked films. We did not observe a 445 significant change in MC3T3-E1 cell adhesion on the surfaces of the uncoated substrates, 446 uncrosslinked films, and crosslinked films (Figure 3 and S4) . However, CH/HA film crosslinking 447 enhanced cell MC3T3-E1 cell proliferation over 6 days compared to uncrosslinked films, leading 448 to a similar number of cells as the bare titanium surface (Figure 3) . These results demonstrate that 449 film crosslinking leads to coatings that can support MC3T3-E1 cell viability and proliferation, 450 Following the fabrication of crosslinked CH/HA films on titanium substrates, β-peptide 454 (ACHC-β 3 hVal-β 3 hLys)3 was loaded into the films by incubating the films in a 0.15 M NaCl 455 solution containing the β-peptide [43, 46, 47] . For selective bacterial biofilm prevention without 456 toxicity to mammalian cells, β-peptide must elute to achieve a local concentration toxic to S. aureus 457 but nontoxic to MC3T3-E1 preosteoblast cells. Therefore, we investigated the effects of varying 458 the concentration of β-peptide in the loading solution on S. aureus and MC3T3-E1 cell viability 459 after being cultured for 24 hr on uncoated titanium, on film-coated substrates lacking β-peptide, 460
and on film-coated substrates loaded with β-peptide ( Figure 4A ). This approach of reporting β-461 peptide loading concentration was used due to difficulties associated with accurately quantifying 462 the amount of β-peptide loaded into the films (e.g. by post-loading extraction). Past studies from 463 our group have shown that varying β-peptide concentration in the loading solution leads to 464 consistent and measurable differences in both the amount of β-peptide loaded and the release 465 profiles of β-peptide from the films [43,46,65]. Our results demonstrate that the extents of S. aureus 466 biofilm inhibition and toxicity toward MC3T3-E1 cells were dependent upon the concentration of 467 β-peptide in the loading solution ( Figure 4A) . A β-peptide loading solution concentration of 0.44 468 mg/mL lead to coatings that completely inhibited S. aureus biofilm formation and maintained at 469 least 50% survival of MC3T3-E1 cells at 24 hr ( Figure 4A ). Thus, this loading concentration was 470 selected for further characterization of antimicrobial activity and biocompatibility of β-peptide-471 containing films. 472
We next investigated the kinetics of β-peptide release from crosslinked CH/HA films on 473 titanium substrates by incubating uncoated titanium, films lacking β-peptide, and films loaded with 474 β-peptide in deionized water for predetermined amounts of time. Figure 4B shows the cumulative 475 release profile of β-peptide (ACHC-β 3 hVal-β 3 hLys)3 from crosslinked films over a period of 54 476 days. Our results reveal that β-peptide is released gradually at a constant rate of 4.6 ± 2.2 477 µg/cm 2 /day over a period of 28 days. Over this period, the crosslinked films released 139.4 ± 20.9 478 µg/cm 2 of β-peptide. The release profile reported in this study is different from previously 479 published profiles for the release of β-peptide from CH/HA films fabricated on the inner lumens of 480 catheter tube segments, which eluted approximately 350 µg/mL of β-peptide over a period of 100-481 150 days [43, 47] . We note that, for the purposes of this study achieving β-peptide release quantities 482 that were selective to S. aureus vs MC3T3-E1 cells was a primary focus; the β-peptide 483 concentration selected for loading these films was thus significantly lower than that used in our 484 previous studies. In addition, chemical crosslinking of CH/HA films, differences in β-peptide 485 sequence, the changes in underlying substrate properties and film-fabrication protocols (e.g., 486
immersion versus flow-based methods) could also contribute to these differences in loading and 487 release. We note further that the release profile reported here is appropriate in the context of IFDs, 488 because the constant rate of β-peptide release was tuned to achieve β-peptide concentrations near 489 the S. aureus biofilm MIC (4 µg/mL, Figure 1 ) over extended periods of time. Also, the localized 490 release of β-peptide reported here is promising in the context of achieving sub-MIC drug 491 concentrations at specific high risk sites, such as IFDs surfaces, which not only results in enhanced 492 effectiveness against preventing S. aureus biofilms but also reduces the possibility of microbial 493 cells developing β-peptide resistance [66]. Finally, by controlling the β-peptide release 494 concentration we also reduce potential β-peptide toxicity against MC3T3-E1 preosteoblast cells, 495 thereby mitigating adverse effects on osseointegration. 496
Finally, we also evaluated how the film thickness changed upon the chemical crosslinking of 497 these films and upon β-peptide incorporation [43, 46] . We used a focused ion beam-scanning 498 electron microscope (FIB-SEM) to generate vertical cross-section images of noncrosslinked films, 499 crosslinked films lacking β-peptide, and crosslinked films loaded with β-peptide. Crosslinked films 500 incubated in β-peptide solution had a thickness of 705 ± 146 nm ( Figure 4D , S1), significantly 501 greater than crosslinked films lacking β-peptide (148 ± 90 nm; p < 0.001; Figure 4C , S1). The 502 thickness of noncrosslinked films (224 ± 73 nm) was not significantly different from the thickness 503 of crosslinked films ( Figure S1 ). The increase in film thickness after loading with β-peptide is in 504 accordance with those of previous studies on uncrosslinked CH/HA films fabricated using other 505 methods [43, 46] . 506 Figure 4 : β-peptide loading and release from titanium substrates coated with crosslinked CH/HA films. 19.5 bilayer thick CH/HA films were deposited and crosslinked for 16 hr using an EDC/NHS solution in 0.15 M NaCl. Incorporation of β-peptide was performed by incubating the films for 24 hr in a β-peptide solution in deionized water containing 0.15M NaCl. A) Quantification of S. aureus and MC3T3-E1 cell viability on β-peptide loaded CH/HA films as a function of β-peptide loading concentration. After CH/HA film fabrication and β-peptide loading, S. aureus or MC3T3-E1 cells were inoculated on the films and allowed to grow for 24 hr. Viabilities were quantified using XTT and Cell Titer Glo assays, respectively. B) Plot showing the cumulative release of β-peptide into PBS (750 µL) at 37°C as a function of time. β-Peptide release concentrations were quantified by using the Pierce quantitative fluorometric assay, calibrated with a standard curve generated with known β-peptide concentrations. C-D) Representative FIB-SEM images of PEM film cross-sections c) before and D) after β-peptide loading. White arrows denote the film edges. Scale bar: 3 µm. Data points represent the mean values and error bars are the standard deviation of three independent experiments.
β peptide-containing coatings inhibit S. aureus biofilms 508
The antimicrobial activity of titanium substrates coated with β-peptide-containing films was 509 characterized by incubating uncoated titanium, coatings without β-peptide, and coatings loaded 510 with β-peptide with an inoculum of 10 6 S. aureus CFU/mL in MH medium supplemented with 511 0.5% glucose at 37°C for 24 hr. The extent of biofilm formation was then evaluated i) qualitatively 512 by inspecting biofilm density using the GFP-expressing S. aureus strain (AH1756) and SEM 513 imaging for characterization of biofilm morphology, and ii) quantitatively by measuring biofilm 514 metabolic activity via an XTT assay. The fluorescence micrographs in Figure 5A -C reveal that 515 robust biofilms formed on the surfaces of uncoated titanium and film-coated titanium substrates 516 without β-peptide, but that β-peptide-loaded films completely inhibited biofilm formation. SEM 517 images reveal biofilms on uncoated substrates and substrates coated with control films without β-518 peptide to be composed of spherical bacterial 3D cell clusters encased by matrix ( Figure 5D -E and 519 Figure S5 ). In contrast, biofilm was not observed on β-peptide-loaded films by SEM imaging 520 ( Figure 5F and Figure S5 ), in accordance with the fluorescence micrographs. Finally, quantification 521 of S. aureus metabolic activity ( Figure 5G ) confirmed a virtual elimination of biofilm on β-peptide-522 loaded coatings, compared to uncoated substrates and films lacking β-peptide. Overall, these 523 results demonstrate that these β-peptide loaded coatings can prevent S. aureus biofilm formation 524 on the surfaces of titanium substrates. 525 Figure 5 : Evaluation S. aureus biofilm formation on titanium substrates coated with β-peptideloaded CH/HA films. Uncoated, crosslinked CH/HA film-coated, and crosslinked CH/HA filmcoated and β-peptide loaded titanium substrates were incubated for 24 hr with S. aureus cells (10 6 CFU/mL) in biofilm inducing conditions (37°C, MH medium + 0.5% glucose). A-C) Representative fluorescence micrographs of GFP-expressing S. aureus strain AH1726 biofilms formed on the surfaces of A) uncoated, B) crosslinked film-coated (19.5 CH/HA bilayers) and C) crosslinked film-coated (19.5 CH/HA bilayers) β-peptide-loaded (0.44 mg/mL for 24 hr) titanium substrates. D-F) Representative SEM images showing the morphology of S. aureus biofilms formed on the surface of D) uncoated, E) crosslinked CH/HA film-coated and F) βpeptide-loaded crosslinked CH/HA film-coated titanium substrates. Scale bar: 10 µm. G) Quantification of live S. aureus cells on uncoated, crosslinked CH/HA film-coated, and βpeptide-loaded crosslinked CH/HA film-coated titanium substrates. S. aureus cell viability was quantified using an XTT metabolic activity assay and normalized to the uncoated control. Data points represent the mean values and error bars are the standard deviation of three independent experiments. Asterisks (*) indicate p < 0.01 by two-way ANOVA using Tukey's multiple comparison test.
Following this proof-of-concept demonstration that β-peptide-containing coatings can prevent 527 S. aureus biofilm formation in the short-term, we also evaluated their ability to resist S. aureus 528 biofilm formation at longer time points, after some of the β-peptide had eluted from the films. For 529 these experiments, we incubated titanium substrates coated with β-peptide-loaded films in PBS for 530 up to 60 days, replacing the PBS solution every 2 days. At desired time points, substrates were 531 challenged with an S. aureus inoculum and biofilm formation was assessed 24 hr later. Results 532 shown in Figure 6A demonstrate that coatings loaded with β-peptide virtually eliminated the 533 formation of S. aureus biofilms for up to 24 days after initiation of β-peptide elution. After 36 534 days, we also observed significant decreases in biofilm, with about 60% less biofilm on coatings 535 loaded with β-peptide compared to bare titanium ( Figure 6A ). This extended inhibition of biofilm 536 formation is consistent with the gradual release of β-peptides from the coatings over a period of 28 537 days (Figure 4) . 538
Finally, we evaluated the ability of the β-peptide-loaded films to resist multiple bacterial 539 challenges, as might occur after implantation of an orthopaedic device in vivo. We presented the 540 substrates with five inocula of S. aureus cells for 24 hr each, washing the substrates between 541 challenges ( Figure 6B ). As demonstrated in Figure 6C , the β-peptide-loaded coatings inhibited S. 542 aureus biofilms after being challenged 5 times over a period of 18 days. However, the extent of 543 biofilm inhibition was reduced for the last three challenges (~75% biofilm inhibition relative to 544 uncoated control) compared to the first two challenges (~99% biofilm inhibition relative to 545 uncoated control) ( Figure 6C ). Fluorescence micrographs of the biofilms formed on the surfaces of 546 uncoated titanium surfaces, coatings lacking β-peptide, and coatings loaded with β-peptide 547 confirmed the quantitative results reported in Figure 6C . Fluorescence micrographs acquired during 548 the first two challenges demonstrate complete inhibition of S. aureus biofilms ( Figure S6G and H) 549 compared to uncoated substrates and control films lacking β-peptide ( Figure S6A -B, D-E). 550 However, following the fifth challenge we did not observe complete inhibition of biofilms on β-551 peptide-loaded coatings. In this instance, we observed the formation of less robust biofilms on β-552 peptide-loaded films ( Figure S6I ) as compared to uncoated titanium and control films lacking β-553 peptide ( Figure S6C and F) . 554 Figure 6 : Quantification of S. aureus biofilm inhibition by β-peptide-loaded CH/HA films on titanium substrates after β-peptide elution in PBS for extended time and multiple short-term challenges. Uncoated, crosslinked film-coated (19.5 CH/HA bilayers), and crosslinked filmcoated (19.5 CH/HA bilayers) and β-peptide loaded (0.44 mg/mL for 24 hr) titanium substrates were incubated for 24 hr with S. aureus cells (10 6 CFU/mL) in biofilm inducing conditions (37°C, MH medium + 0.5% glucose). A) Long-term antimicrobial activity of uncoated, crosslinked film-coated and crosslinked film-coated β-peptide-loaded titanium substrates after being pre-incubated in PBS and challenged with S. aureus. B) Schematic for the protocol used when performing multiple S. aureus challenge experiments. Uncoated, crosslinked film-coated, and crosslinked film-coated and β-peptide loaded titanium substrates were challenged with an S. aureus inoculum for 24 hrs, followed by incubation in PBS for the specified period of time. These challenges were repeated until a total of 5 different challenges was performed. C) Antimicrobial activity of uncoated, film-coated, and β peptide post-loaded titanium substrates after multiple challenges with S. aureus inoculum. S. aureus cell viability was quantified using an XTT metabolic activity assay and normalized to the uncoated control. Data points represent the mean values and error bars are the standard deviation of three independent experiments. Asterisks (*) indicate p ≤ 0.05 between Ti and Ti/crosslinked film, # indicates p ≤ 0.05 between Ti and Ti/crosslinked film/Pep, and & indicates p < 0.01 between Ti/crosslinked film and Ti/crosslinked film/Pep by two-way ANOVA using Tukey's multiple comparison test.
In summary, the results presented here suggest that crosslinked CH/HA films loaded with an 556 antimicrobial β-peptide may be a promising approach for inhibiting S. aureus colonization and 557 biofilm formation on titanium IFDs after implantation ( Figure 5) , with the ability to resist multiple 558 S. aureus challenges and prevent biofilm formation for several weeks. These results may improve 559 on the short-term antimicrobial activity of current coatings focused on titanium surface 560 modifications for preventing S. aureus cell attachment [52,67,68] and demonstrate the effectiveness 561 in preventing biofilms after eluting relevant antibiotic quantities in short time-periods (e.g., hours 562 to days only) [22,52,54,69]. Additionally, our results demonstrate inhibition of S. aureus biofilms 563 in a time frame (e.g., 3 months after surgical implantation) at which patients are most susceptible 564 to microbial colonization. Therefore, our proposed therapeutic approach could potentially improve 565 healing and further prevent implant failure in healthcare settings [15] . 566 567 3.4. β-peptide-containing coatings elute β-peptide concentrations biocompatible with 568
MC3T3-E1 cells 569
Many antimicrobial strategies have been reported for the prevention of implant-related 570 bacterial infections. The adaptation of these strategies to orthopaedic implants should consider their 571 biocompatibility with the bone microenvironment, including potential effects on bone cells 572 [18,53,68]. Our results described above demonstrate that β-peptides in solution can prevent S. 573 aureus biofilm formation with minimal toxicity against MC3T3-E1 cells. In addition, release of 574 antimicrobial β-peptides from crosslinked films on titanium can prevent S. aureus biofilm 575 formation. We next assessed the biocompatibility of our β-peptide-containing coatings incubated 576 directly with MC3T3-E1 cells. The cytotoxicity of β-peptide-loaded films was evaluated by 577 seeding MC3T3-E1 cells (5 x10 4 cells/cm 2 ) on the surface of uncoated titanium surfaces and PEM 578 films loaded with β-peptide. MC3T3-E1 viability was quantified via a Cell Titer Glo assay after 24 579 hr. Our results demonstrate that films loaded with β-peptide (Figure 7 , green bars) supported a 580 similar extent of attachment of MC3T3-E1 cells after 24 hr compared to uncoated titanium ( Figure  581 7, blue bars), suggesting that they are non-toxic to preosteoblast cells and exhibit good 582 biocompatibility. Taken together with the results demonstrating S. aureus biofilm inhibition under 583 these same conditions ( Figure 5 ), these results indicate that β-peptide loaded films can be designed 584 to elute β-peptide quantities that prevent S. aureus biofilms but do not cause substantial MC3T3-585 E1 cell toxicity. 586
We also quantified the viability of MC3T3-E1 preosteoblast cells on β-peptide-loaded coatings 587 formed on titanium substrates after β-peptide elution in PBS for up to 60 days prior to MC3T3-E1 588 cell seeding. The viability of the MC3T3-E1 cells on films loaded with β-peptide was not 589 significantly different than viability on bare titanium (Figure 7) . When taken together, these long-590 term MC3T3-E1 viability results (Figure 7 ) and the long-term biofilm inhibition prevention assay 591 ( Figure 6A ) demonstrate the selectivity of films loaded with β-peptide for inhibiting S. aureus 592 biofilms without inducing MC3T3-E1 cell toxicity for prolonged periods. 593
Conclusions 595
This study used a layer-by-layer based approach to fabricate crosslinked CH/HA PEM 596 films on titanium substrates. These films supported MC3T3-E1 preosteoblast cell attachment and 597 proliferation for up to 6 days. We also demonstrated the incorporation of an antimicrobial β-598 peptide within the crosslinked CH/HA films to yield coatings that release β-peptide over a period 599 of 28 days, which is relevant in the context of inhibiting bacterial attachment and biofilm formation 600 over short to medium-term time periods. Furthermore, we showed that films loaded with β-peptide 601 successfully prevented S. aureus biofilms formation in vitro without significantly decreasing 602 MC3T3-E1 viability, suggesting promise for these films in the context of developing orthopaedic 603 implant surfaces that resist biofilm formation. This result suggests promise toward developing 604 Figure 7 . Evaluation of MC3T3-E1 cell viability on β-peptide-loaded CH/HA film-coated titanium substrates for extended periods of time. Uncoated, substrates and β-peptide-containing crosslinked CH/HA film-coated titanium substrates were incubated for 24 hr with MC3T3-E1 cells (5x10 4 cells/cm 2 ). Cell viability was quantified using a Cell Titer Glo assay and normalized to uncoated control. Data points represent the mean values and error bars are the standard deviation of three independent experiments. No significant differences were found between Ti and Ti/crosslinked film/Pep by two-way ANOVA using Tukey's multiple comparison test.
